Quantification of circulating endothelial cells as a predictor of response to chemotherapy with platinum and pemetrexed in patients with advanced non-squamous non-small cell lung carcinoma
Por:
Hernandez, A, Juan, O, Martinez, J, Blanco, R, Macia, S, Galiana, G, Aparisi, F, Noguera, J, Catot, S, Gaspa, F and Garcia-Pinon, F
Publicada:
1 abr 2015
Resumen:
Circulating endothelial cells (CEC) play an important role in tumor neovascularization and may have prognostic value in cancer patients. This study was designed to investigate the role of CEC as a marker for predicting platinum plus pemetrexed first-line chemotherapy efficacy in advanced non-squamous non-small cell lung cancer (NSCLC).
A prospective study was performed whose main objective was to study whether the numbers of CEC at baseline and prior to the second and third cycle of chemotherapy were response predictors. Sixty-nine patients received cisplatin plus pemetrexed, and peripheral blood samples were performed at baseline and after second and third cycle. Separation and CEC count were performed using inmunomagnetic separation (CellSearch).
The CEC count in 4 mL of peripheral blood was obtained prior to the first, second, and third cycle of treatment. Baseline levels and evolution of CEC were correlated with response to treatment according to RECIST criteria after three cycles of treatment. Sixty-nine patients were included: 43 (64.2 %) received cisplatin/pemetrexed and 24 (35.8 %) carboplatin/pemetrexed. Range of baseline CEC: 8-965 (mean of 153 cel/4 mL). The results after 3 cycles were: 25 partial responses (36.2 %), 17 cases of stabilization of disease (24.6 %), 16 of progressive disease (23.2 %) and 11 non-evaluables (16 %). No significant relationship between the baseline CEC count and response was found (p value = 0.831). Increase > 50 % between the first and second cycle was correlated significantly with progression disease (p = 0.008). Patients who had a baseline CEC count greater than the mean (> 153 cells/4 mL) showed longer progression-free survival and global survival without statistical significance.
In this homogeneous group of patients with NSCLC, there is no correlation between response to treatment and CEC baseline levels. The increase in CEC numbers after the first cycle could be a negative predictive factor.
Filiaciones:
Hernandez, A:
Consorcio Hosp Prov Castellon, Serv Oncol Med, Castellon de La Plana 12003, Spain
Juan, O:
Hosp Univ & Politecn Fe, Med Oncol Serv, Valencia, Spain
:
Hosp Arnau Vilanova, Serv Anal Clin, Valencia 46015, Spain
Blanco, R:
Hosp Mutua de Terrassa, Med Oncol Serv, Barcelona 08221, Spain
:
Hosp Gen Elda, Med Oncol Serv, Alicante 03600, Spain
Galiana, G:
Clin Benidorm, Med Oncol Serv, Alicante 03501, Spain
:
Hosp Virgen de los Lirios, Med Oncol Serv, Alicante 03804, Spain
:
Hosp Arnau Vilanova, Med Oncol Serv, Valencia 46015, Spain
Catot, S:
Clin Althaia de Manresa, Med Oncol Serv, Barcelona 08243, Spain
Gaspa, F:
Hosp St Joan dEspi Moises Broggi, Med Oncol Serv, Barcelona 08970, Spain
Garcia-Pinon, F:
Hosp Prov Castellon, Fdn Comunidad Valenciana, Castellon de La Plana 12003, Spain
|